Fintel reports that on October 13, 2025, BTIG maintained coverage of Zimmer Biomet Holdings (NYSE:ZBH) with a Buy ...

Zimmer Biomet is undervalued despite recent underperformance, backed by innovation, acquisitions, and strong cash flow. Learn ...

Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet (ZBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two companies is the best ...

Fintel reports that on October 7, 2025, Evercore ISI Group maintained coverage of Zimmer Biomet Holdings (NYSE:ZBH) with a In ...

Zimmer Biomet Holdings (ZBH) just made headlines with a major regulatory milestone, gaining approval from Japan's Pharmaceutical and Medical Devices Agency for its iTaperloc Complete and iG7 Hip ...

Zimmer (ZBH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The S&P 500 added 0.4% Wednesday, but only after jumping toward one of its biggest gains since the summer, erasing it all and then climbing back. The Nasdaq composite climbed 0.7%, and the Dow Jones ...

But here’s the BEST one in my book...and it’s one you probably haven’t seen. This MoneyShow Chart of the Day shows the 2-year ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $114.0, with a high estimate of $130.00 and a low estimate of $96.00. Observing a 5.88% ...

Zimmer Biomet (NYSE: ZBH) announced yesterday that it launched two new solutions for complex foot and ankle trauma.

London-based QSM Asset Management acquired 174,700 shares of Rio Tinto Group for an estimated $11.5 million in the third quarter. QSM Asset Management disclosed a new position in Rio Tinto Group on ...